MedTrace Logo

Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)

NCT07297186 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2025-12-22

No results posted yet for this study

Summary

The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60\~89 days).

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

sIPV

sIPVs were developed by Biominhai (Beijing Minhai Biotechnology Co. Ltd.)

BIOLOGICAL

wIPV

wIPVs were developed by Sanofi Pasteur

Sponsors & Collaborators

  • Beijing Minhai Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Days
Max Age
89 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-21
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07297186 on ClinicalTrials.gov